Naseem Zojwalla
Chief Tech/Sci/R&D Officer bij OLEMA PHARMACEUTICALS, INC.
Vermogen: 909 720 $ op 31-03-2024
Profiel
Naseem Zojwalla currently works at Peloton Therapeutics, Inc., as Head-Clinical Development & Strategy, Turning Point Therapeutics, Inc., as Vice President-Clinical Development, Columbia University Medical Center, as Assistant Clinical Professor-Medicine, and Olema Pharmaceuticals, Inc., as Chief Medical Officer from 2022.
Dr. Zojwalla received her undergraduate degree from Stanford University and doctorate degree from Temple University School of Medicine.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 18-03-2024 | 80 364 ( 0.14% ) | 909 720 $ | 31-03-2024 |
Actieve functies van Naseem Zojwalla
| Bedrijven | Functie | Begin |
|---|---|---|
| OLEMA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 31-01-2022 |
| TURG POIN | Chief Tech/Sci/R&D Officer | - |
| PELOTON THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
| Columbia University Medical Center | Corporate Officer/Principal | - |
Opleiding van Naseem Zojwalla
| Stanford University | Undergraduate Degree |
| Temple University School of Medicine | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| OLEMA PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Peloton Therapeutics, Inc.
 Peloton Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in translating novel scientific insights into medicines for patients with cancer and other debilitating or life-threatening conditions. Its lead drug candidate is a small molecule which targets HIF-2a, a transcription factor implicated in the development and progression of renal and other cancers. The company was founded by Steven L. McKnight in August 2010 and is headquartered in Dallas, TX. | Health Technology |
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
